Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/GLB1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/GLB1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/GLB1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/GLB1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/GLB1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/GLB1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/GLB1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00442826 | Oral cavity | OSCC | small molecule catabolic process | 174/7305 | 376/18723 | 2.25e-03 | 1.00e-02 | 174 |
GO:00066641 | Oral cavity | OSCC | glycolipid metabolic process | 53/7305 | 100/18723 | 3.09e-03 | 1.33e-02 | 53 |
GO:00513024 | Oral cavity | OSCC | regulation of cell division | 87/7305 | 177/18723 | 3.75e-03 | 1.55e-02 | 87 |
GO:00324652 | Oral cavity | OSCC | regulation of cytokinesis | 49/7305 | 92/18723 | 3.81e-03 | 1.57e-02 | 49 |
GO:19035091 | Oral cavity | OSCC | liposaccharide metabolic process | 53/7305 | 101/18723 | 4.06e-03 | 1.66e-02 | 53 |
GO:00481022 | Oral cavity | OSCC | autophagic cell death | 9/7305 | 11/18723 | 4.85e-03 | 1.92e-02 | 9 |
GO:001605210 | Oral cavity | OSCC | carbohydrate catabolic process | 76/7305 | 154/18723 | 5.67e-03 | 2.18e-02 | 76 |
GO:00440903 | Oral cavity | OSCC | positive regulation of vacuole organization | 10/7305 | 13/18723 | 6.32e-03 | 2.35e-02 | 10 |
GO:00442625 | Oral cavity | OSCC | cellular carbohydrate metabolic process | 130/7305 | 283/18723 | 9.98e-03 | 3.49e-02 | 130 |
GO:007259419 | Oral cavity | LP | establishment of protein localization to organelle | 205/4623 | 422/18723 | 6.76e-27 | 3.85e-24 | 205 |
GO:0006605110 | Oral cavity | LP | protein targeting | 156/4623 | 314/18723 | 5.43e-22 | 1.62e-19 | 156 |
GO:001623615 | Oral cavity | LP | macroautophagy | 135/4623 | 291/18723 | 4.71e-16 | 6.70e-14 | 135 |
GO:1903829110 | Oral cavity | LP | positive regulation of cellular protein localization | 127/4623 | 276/18723 | 7.52e-15 | 9.81e-13 | 127 |
GO:000683919 | Oral cavity | LP | mitochondrial transport | 119/4623 | 254/18723 | 1.06e-14 | 1.33e-12 | 119 |
GO:007058519 | Oral cavity | LP | protein localization to mitochondrion | 70/4623 | 125/18723 | 6.73e-14 | 7.02e-12 | 70 |
GO:007265519 | Oral cavity | LP | establishment of protein localization to mitochondrion | 68/4623 | 120/18723 | 6.98e-14 | 7.16e-12 | 68 |
GO:0031647110 | Oral cavity | LP | regulation of protein stability | 132/4623 | 298/18723 | 8.16e-14 | 7.99e-12 | 132 |
GO:003238616 | Oral cavity | LP | regulation of intracellular transport | 145/4623 | 337/18723 | 8.58e-14 | 8.27e-12 | 145 |
GO:003238819 | Oral cavity | LP | positive regulation of intracellular transport | 97/4623 | 202/18723 | 4.79e-13 | 4.30e-11 | 97 |
GO:003315719 | Oral cavity | LP | regulation of intracellular protein transport | 106/4623 | 229/18723 | 7.85e-13 | 6.68e-11 | 106 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GLB1 | SNV | Missense_Mutation | | c.1336N>C | p.Ala446Pro | p.A446P | P16278 | protein_coding | tolerated(0.2) | possibly_damaging(0.897) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
GLB1 | SNV | Missense_Mutation | novel | c.302N>G | p.Asp101Gly | p.D101G | P16278 | protein_coding | tolerated(0.07) | possibly_damaging(0.863) | TCGA-E9-A245-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
GLB1 | SNV | Missense_Mutation | | c.1628N>T | p.Ser543Leu | p.S543L | P16278 | protein_coding | tolerated(0.14) | possibly_damaging(0.543) | TCGA-GM-A2DF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
GLB1 | SNV | Missense_Mutation | | c.592N>C | p.Asp198His | p.D198H | P16278 | protein_coding | deleterious(0.05) | possibly_damaging(0.9) | TCGA-LL-A5YO-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
GLB1 | insertion | Frame_Shift_Ins | novel | c.1526_1527insCG | p.Trp509CysfsTer92 | p.W509Cfs*92 | P16278 | protein_coding | | | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
GLB1 | insertion | Frame_Shift_Ins | novel | c.1524_1525insATGGGGGAAAGGGAATCTTCCCACAT | p.Trp509MetfsTer100 | p.W509Mfs*100 | P16278 | protein_coding | | | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
GLB1 | insertion | Frame_Shift_Ins | novel | c.1909_1910insGTGTACATAGTATGGTATATCT | p.Thr637SerfsTer29 | p.T637Sfs*29 | P16278 | protein_coding | | | TCGA-BH-A0H7-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
GLB1 | deletion | Frame_Shift_Del | novel | c.237delN | p.Ile80SerfsTer41 | p.I80Sfs*41 | P16278 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
GLB1 | SNV | Missense_Mutation | novel | c.790N>A | p.Leu264Met | p.L264M | P16278 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-EA-A3Y4-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
GLB1 | SNV | Missense_Mutation | | c.423N>T | p.Glu141Asp | p.E141D | P16278 | protein_coding | tolerated(0.18) | benign(0.006) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |